PL3580208T3 - Pochodne 2-(3-(1H-benzo[d]imidazol-1-ilo)propylo)piperydyn-3-olu i związki pokrewne jako inhibitory prs do leczenia np. raka - Google Patents
Pochodne 2-(3-(1H-benzo[d]imidazol-1-ilo)propylo)piperydyn-3-olu i związki pokrewne jako inhibitory prs do leczenia np. rakaInfo
- Publication number
- PL3580208T3 PL3580208T3 PL18750794T PL18750794T PL3580208T3 PL 3580208 T3 PL3580208 T3 PL 3580208T3 PL 18750794 T PL18750794 T PL 18750794T PL 18750794 T PL18750794 T PL 18750794T PL 3580208 T3 PL3580208 T3 PL 3580208T3
- Authority
- PL
- Poland
- Prior art keywords
- prs
- imidazol
- piperidin
- benzo
- inhibitors
- Prior art date
Links
- XQFFAYVXXVVJCT-UHFFFAOYSA-N N1(C=NC2=C1C=CC=C2)CCCC1NCCCC1O Chemical class N1(C=NC2=C1C=CC=C2)CCCC1NCCCC1O XQFFAYVXXVVJCT-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170016971 | 2017-02-07 | ||
| EP18750794.2A EP3580208B1 (en) | 2017-02-07 | 2018-02-07 | 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol derivatives and related compounds as prs inhibitors for treating e.g. cancer |
| PCT/KR2018/001625 WO2018147626A1 (en) | 2017-02-07 | 2018-02-07 | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3580208T3 true PL3580208T3 (pl) | 2021-12-27 |
Family
ID=63107680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18750794T PL3580208T3 (pl) | 2017-02-07 | 2018-02-07 | Pochodne 2-(3-(1H-benzo[d]imidazol-1-ilo)propylo)piperydyn-3-olu i związki pokrewne jako inhibitory prs do leczenia np. raka |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10981917B2 (pl) |
| EP (1) | EP3580208B1 (pl) |
| JP (1) | JP6785384B2 (pl) |
| KR (1) | KR102084772B1 (pl) |
| CN (1) | CN110191882B (pl) |
| AR (1) | AR110963A1 (pl) |
| AU (1) | AU2018218965B2 (pl) |
| CA (1) | CA3049643C (pl) |
| CL (1) | CL2019002019A1 (pl) |
| CO (1) | CO2019007834A2 (pl) |
| DO (1) | DOP2019000193A (pl) |
| EC (1) | ECSP19051409A (pl) |
| ES (1) | ES2899665T3 (pl) |
| HR (1) | HRP20211483T1 (pl) |
| HU (1) | HUE056218T2 (pl) |
| MA (1) | MA47469B1 (pl) |
| MX (1) | MX391440B (pl) |
| MY (1) | MY196538A (pl) |
| PE (1) | PE20191477A1 (pl) |
| PH (1) | PH12019501811A1 (pl) |
| PL (1) | PL3580208T3 (pl) |
| PT (1) | PT3580208T (pl) |
| RS (1) | RS62541B1 (pl) |
| RU (1) | RU2733384C1 (pl) |
| SA (1) | SA519402180B1 (pl) |
| SG (1) | SG11201906436VA (pl) |
| SI (1) | SI3580208T1 (pl) |
| TN (1) | TN2019000204A1 (pl) |
| TW (4) | TWI782525B (pl) |
| WO (1) | WO2018147626A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7352284B2 (ja) * | 2017-05-15 | 2023-09-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体 |
| SG11202111244XA (en) | 2019-04-12 | 2021-11-29 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
| KR102346187B1 (ko) * | 2019-12-26 | 2021-12-31 | 울산과학기술원 | 디히드로퓨란 유도체 및 이의 합성 방법 |
| EP4338733A4 (en) | 2021-05-13 | 2025-05-07 | Daewoong Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION INTENDED FOR THE PREVENTION OR TREATMENT OF FIBROSIS |
| PE20241171A1 (es) * | 2021-05-13 | 2024-05-28 | Daewoong Pharmaceutical Co Ltd | Composicion farmaceutica para prevenir o tratar la fibrosis |
| KR102997524B1 (ko) | 2021-07-23 | 2026-07-29 | 주식회사 대웅제약 | 전신경화증의 예방 또는 치료용 약학적 조성물 |
| US12686665B2 (en) | 2021-10-01 | 2026-07-21 | Yuhan Corporation | Bicyclic fused ring derivative or salt thereof and pharmaceutical composition comprising same |
| CN118401508A (zh) * | 2021-12-17 | 2024-07-26 | 株式会社大熊制药 | (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形 |
| KR102798169B1 (ko) | 2021-12-17 | 2025-04-21 | 주식회사 대웅제약 | (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법 |
| JP2025523364A (ja) * | 2022-06-08 | 2025-07-23 | デウン ファーマシューティカル カンパニー リミテッド | アルギナーゼ阻害剤およびこれを含む薬学的組成物 |
| JP2025529524A (ja) * | 2022-10-12 | 2025-09-04 | デウン ファーマシューティカル カンパニー リミテッド | 腎臓炎の予防または治療用薬学的組成物 |
| KR20240069303A (ko) | 2022-11-11 | 2024-05-20 | 주식회사 대웅제약 | 방출 제어형 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| ATE174915T1 (de) | 1994-10-31 | 1999-01-15 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren |
| IL114951A (en) | 1995-08-15 | 1999-08-17 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization |
| DE59710417D1 (de) | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| EP1208177A1 (en) * | 1999-08-20 | 2002-05-29 | CSL Silicones Inc. | One-part organopolysiloxane rubber composition for use as a corrosion protection coating |
| MXPA03008180A (es) | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Inhibidores de metaloproteinasa. |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| ATE489138T1 (de) | 2005-04-13 | 2010-12-15 | Neuraxon Inc | Substituierte indolverbindungen mit nos-hemmender aktivität |
| JPWO2007034882A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| JP2010519186A (ja) | 2007-02-19 | 2010-06-03 | スミスクライン ビーチャム コーポレーション | 免疫調節物質としてのプリン誘導体 |
| CN102176911B (zh) * | 2008-08-11 | 2014-12-10 | 葛兰素史密丝克莱恩有限责任公司 | 新的腺嘌呤衍生物 |
| CA2737219C (en) * | 2008-08-11 | 2017-02-28 | Tracy Keller | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| JP2015517994A (ja) | 2012-03-29 | 2015-06-25 | ヘイロー セラピューティックス， エルエルシー | ハロフジノンの剤形およびその使用 |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| JP6272510B2 (ja) | 2014-06-23 | 2018-01-31 | デウン ファーマシューティカル カンパニー リミテッド | 新規なヘテロ環化合物 |
| KR102277538B1 (ko) | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
-
2018
- 2018-02-06 AR ARP180100277A patent/AR110963A1/es active IP Right Grant
- 2018-02-07 RU RU2019124878A patent/RU2733384C1/ru active
- 2018-02-07 RS RS20211375A patent/RS62541B1/sr unknown
- 2018-02-07 PL PL18750794T patent/PL3580208T3/pl unknown
- 2018-02-07 EP EP18750794.2A patent/EP3580208B1/en active Active
- 2018-02-07 AU AU2018218965A patent/AU2018218965B2/en active Active
- 2018-02-07 TN TNP/2019/000204A patent/TN2019000204A1/en unknown
- 2018-02-07 PT PT187507942T patent/PT3580208T/pt unknown
- 2018-02-07 WO PCT/KR2018/001625 patent/WO2018147626A1/en not_active Ceased
- 2018-02-07 MY MYPI2019004122A patent/MY196538A/en unknown
- 2018-02-07 TW TW110116961A patent/TWI782525B/zh active
- 2018-02-07 TW TW109107089A patent/TWI772759B/zh active
- 2018-02-07 MA MA47469A patent/MA47469B1/fr unknown
- 2018-02-07 MX MX2019009185A patent/MX391440B/es unknown
- 2018-02-07 PE PE2019001462A patent/PE20191477A1/es unknown
- 2018-02-07 ES ES18750794T patent/ES2899665T3/es active Active
- 2018-02-07 SG SG11201906436VA patent/SG11201906436VA/en unknown
- 2018-02-07 KR KR1020180015091A patent/KR102084772B1/ko active Active
- 2018-02-07 TW TW108107266A patent/TWI700280B/zh active
- 2018-02-07 TW TW107104338A patent/TWI694070B/zh active
- 2018-02-07 CA CA3049643A patent/CA3049643C/en active Active
- 2018-02-07 HU HUE18750794A patent/HUE056218T2/hu unknown
- 2018-02-07 US US16/477,575 patent/US10981917B2/en active Active
- 2018-02-07 JP JP2019542437A patent/JP6785384B2/ja active Active
- 2018-02-07 CN CN201880006571.2A patent/CN110191882B/zh active Active
- 2018-02-07 SI SI201830416T patent/SI3580208T1/sl unknown
- 2018-02-07 HR HRP20211483TT patent/HRP20211483T1/hr unknown
-
2019
- 2019-07-08 SA SA519402180A patent/SA519402180B1/ar unknown
- 2019-07-17 EC ECSENADI201951409A patent/ECSP19051409A/es unknown
- 2019-07-18 CL CL2019002019A patent/CL2019002019A1/es unknown
- 2019-07-22 CO CONC2019/0007834A patent/CO2019007834A2/es unknown
- 2019-07-24 DO DO2019000193A patent/DOP2019000193A/es unknown
- 2019-08-06 PH PH12019501811A patent/PH12019501811A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE056218T2 (hu) | 2-(3-(1H-benzo[d]imidazol-1-il)propil)piperidin-3-ol származékok és kapcsolódó vegyületek mint PRS inhibitorok pl. rák kezelésére | |
| IL268430A (en) | Methods for treating cancer using hsp90 inhibitors | |
| IL275337A (en) | 1-(piperidinocarbonylmethyl)-2-oxopyrazine derivatives for cancer therapy | |
| EP3307713A4 (en) | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA | |
| IL263178A (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| EP3641770A4 (en) | CANCER TREATMENT METHODS | |
| IL263497B (en) | 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment | |
| WO2016179558A8 (en) | K-ras modulators | |
| EP3092255A4 (en) | Compounds and compositions for treating egfr expressing tumors | |
| PL2922828T3 (pl) | Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka | |
| EP3334460A4 (en) | BIOMATERIALS FOR COMBINED RADIOTHERAPY AND IMMUNOTHERAPY OF CANCER | |
| IL277695A (en) | Palladianolide history as spliceosome targeting agents for cancer therapy | |
| HUE067028T2 (hu) | Ribonukleotid reduktáz inhibitor szulfonamid vegyületek vagy sóik rák kezelésére | |
| EP3307068A4 (en) | Mct4 inhibitors for treating disease | |
| IL261774B (en) | Preparations for the treatment of skin problems | |
| FR3024138B1 (fr) | Composition de mortier pour enduit ou revetement d'interieur | |
| ZA202003981B (en) | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof | |
| EP3400300A4 (en) | PROCESS FOR REDUCING LRRK2 EXPRESSION | |
| ZA201907974B (en) | Agent for preventing or treating spinocerebellar ataxia | |
| EP3674398A4 (en) | ECHOVIRUS FOR TUMOR TREATMENT | |
| EP3656397A4 (en) | NEW TARGET FOR CANCER TREATMENT | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| EP3483232A4 (en) | PUNCTURE SEALANT | |
| IL278984A (en) | Spinamide for the treatment of muscle deformity | |
| HK40018007A (en) | Methods for treating cancer using hsp90 inhibitors |